Blincyto (blinatumomab) is a prescription medication used to treat a specific type of blood cancer called B-cell precursor acute lymphoblastic leukemia (ALL). The dosage of Blincyto may vary based on the patient's body weight and the stage of the disease.
The recommended starting dose of Blincyto is 9 micrograms (mcg) per day, which is delivered through a continuous intravenous infusion (IV) for 28 days. After the first 28 days, the dosage is increased to 28 mcg per day for up to 3 additional cycles of 28 days each.
The dosage of Blincyto may need to be adjusted based on the patient's response to treatment and any side effects they experience. In some cases, the treatment may need to be interrupted or discontinued if severe side effects occur.
It is important to follow the dosing instructions provided by the prescribing healthcare provider and to contact them if you have any questions or concerns about your treatment with Blincyto.
Read - Blincyto 38.5 mcg for acute lymphoblastic leukemia
.jpg)
No comments:
Post a Comment